Schmid Peter
Berl Munch Tierarztl Wochenschr. 2014 Nov-Dec;127(11-12):498-512.
The emergence and increasing prevalence of resistant pathogens primarily in intensive care units demand the discovery and development of new antimicrobial agents and new therapeutic approaches. This review provides an overview of new antibacterial agents that are currently in research and development pipelines. Data were collected from published literature, meeting abstracts, public government and company websites. Well-known antibacterial classes like beta-lactams, quinolones, macrolides, tetracyclines, and pleuromutilins are represented by new molecules with enhanced antibacterial or pharmacological properties. Furthermore, compounds acting on targets not previously exploited are in various stages of research and development. Targeting bacterial virulence is an alternative approach to antibacterial therapy. Neutralizing bacterial toxins by using antibodies is an established anti-virulence strategy which encourages increased research into other virulence targets. Certain virulence factors have already been shown to be meaningful targets for small molecules.
主要在重症监护病房出现并日益普遍的耐药病原体，需要发现和开发新的抗菌药物及新的治疗方法。本综述概述了目前处于研发阶段的新型抗菌药物。数据收集自已发表的文献、会议摘要、政府和公司的公开网站。知名抗菌类别如β-内酰胺类、喹诺酮类、大环内酯类、四环素类和截短侧耳素类，都有具有增强抗菌或药理特性的新分子代表。此外，作用于此前未被利用靶点的化合物正处于不同的研发阶段。靶向细菌毒力是抗菌治疗的一种替代方法。使用抗体中和细菌毒素是一种既定的抗毒力策略，这促使人们对其他毒力靶点进行更多研究。某些毒力因子已被证明是小分子的有意义靶点。
